Company intelligence / Profile preview

Profectus

Baltimore, Maryland, United Statesprofectusbc.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 1

Overview

Several vaccine candidates have advanced to Phase I clinical trials, including a candidate for Henipavirus infections. Other pipeline assets targeting Ebola and related viruses are in preclinical development. The company has received significant grant funding from US government agencies to accelerate clinical evaluation of its Ebola vaccines during outbreaks. No commercialized products as of the latest available data.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccines (pDNA)Recombinant viral vector vaccines (rVSV platform)Monoclonal antibodies
Industry: Biotech

Partnerships

U.S. Department of DefenseNational Institutes of HealthBiomedical Advanced Research and Development Authority (BARDA)

Beyond the preview

Go deeper on Profectus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Profectus.

Explore the full profile